HMBS and acute intermittent porphyria: In the case of clinical trials, intravenous administration of AAV particles expressing the porphobilinogen deaminase (PBGD) gene in a phase I trial in patients with acute intermittent porphyria (AIP) did not correct the AIP phenotype but suggested a trend towards a reduction in hospitalization and heme treatment [165].